Skip to main content
Fig. 8 | BMC Cancer

Fig. 8

From: Integrative analysis of a novel signature incorporating metabolism and stemness-related genes for risk stratification and assessing clinical outcomes and therapeutic responses in lung adenocarcinoma

Fig. 8

Analysis of immune checkpoints, HLA, TMB, and TIDE. A It illustrates the differences in immune checkpoint gene expression between high- and low-risk groups. B This panel compares the expression levels of HLA members across the two risk groups. C Mutation mapping of LUAD patients highlights the top 20 genes with the highest mutation frequencies, differentiated by risk group. D A comparison of tumor mutation burden (TMB) among distinct risk groups is shown. E, F These panels display the TIDE values and immunotherapy response results for LUAD patients categorized by risk group. HLA, human leukocyte antigen; TMB, tumor mutation burden; TIDE, tumor immune dysfunction and exclusion. Statistical significance is indicated as *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us